Yung D Kim is a notable inventor based in Lindenhurst, IL (US), recognized for his contributions to immunological methods and materials for the detection of tumor-associated antigens. With a total of 4 patents to his name, he has made significant strides in the field of cancer diagnostics.

Latest Patents

One of his latest patents focuses on immunological methods and materials for the detection of antigens associated with breast or prostate cancer disease states. This invention discloses the use of preferred antibody preparations, such as PR92 monoclonal antibodies produced by hybridoma cell line ATCC HB 9390, in immunoassays performed on patient body fluids. Another significant patent is the antibody adsorbed support method for carcinoembryonic antigen assay. This invention relates to an immunoassay for carcinoembryonic antigen in plasma or sera, where heat-treating the plasma or serum provides a supernatant that is incubated with a solid support having carcinoembryonic antigen antibody adsorbed thereto.

Career Highlights

Yung D Kim is currently associated with Abbott Laboratories Corporation, a leading company in the healthcare sector. His work at Abbott has allowed him to focus on innovative solutions for cancer detection and treatment.

Collaborations

Throughout his career, Yung D Kim has collaborated with notable colleagues, including Joseph T Tomita and Jay R Schenck, contributing to advancements in immunological research and diagnostics.

Conclusion

Yung D Kim's innovative work in immunological detection methods has made a significant impact in the field of cancer diagnostics. His patents reflect a commitment to improving patient outcomes through advanced technology and research.